Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma

Osteosarcoma is the most prevalent bone malignant tumor in children and adolescents, and displays heterogeneous histology and high propensity for distant metastasis. Although adjuvant chemotherapy remarkably improved treatment outcome over the past few decades, prognosis for osteosarcoma patients with pulmonary metastasis is still unsatisfactory. To identify novel therapeutic targets for osteosarcoma, we investigated the gene expression profile of osteosarcomas by cDNA microarray analysis and found transactivation of receptor tyrosine kinase‐like orphan receptor 2 (ROR2) expression in the majority of osteosarcoma samples. Treatment of osteosarcoma cell lines with siRNA against ROR2 significantly inhibited cell proliferation and migration. We also identified wingless‐type MMTV integration site family, member 5B (WNT5B) as a putative ROR2 ligand and that the physiological interaction of WNT5B and ROR2 could enhance cell migration, indicating the possible roles of ROR2 and WNT5B in the metastatic property of osteosarcoma cells. Taken together, our findings revealed that the WNT5B/ROR2 signaling pathway is a promising therapeutic target for osteosarcoma. (Cancer Sci 2009; 100: 1227–1233)

[1]  M. Gebhardt,et al.  Survival Data for 648 Patients with Osteosarcoma Treated at One Institution , 2004, Clinical orthopaedics and related research.

[2]  M. Ladanyi,et al.  MDM2 gene amplification in metastatic osteosarcoma. , 1993, Cancer research.

[3]  S. Jeffery,et al.  One gene, two phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome and autosomal dominant brachydactyly type B , 2003, Human mutation.

[4]  P. Choong,et al.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma , 2006, Clinical & Experimental Metastasis.

[5]  M. Kay,et al.  Sarcoma Derived from Cultured Mesenchymal Stem Cells , 2007, Stem cells.

[6]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[7]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[8]  I. Hiratani,et al.  The Xenopus receptor tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. , 2002, Development.

[9]  Han-Soo Kim,et al.  RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[10]  S. Mundlos,et al.  A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. , 2007, American journal of human genetics.

[11]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[12]  B. Alman,et al.  Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. , 2007, Cancer research.

[13]  M. Longaker,et al.  Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. , 2006, Journal of pediatric surgery.

[14]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[15]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  C. Rodríguez-Galindo,et al.  Metastatic osteosarcoma , 2006 .

[17]  D. Mercola,et al.  The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. , 1990, Oncogene.

[18]  Bhabatosh Chaudhuri,et al.  Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. , 2002, Pharmacology & therapeutics.

[19]  A. Mock,et al.  c-myc amplification and expression in newly established human osteosarcoma cell lines. , 1987, Cancer research.

[20]  C. Rodríguez-Galindo,et al.  Metastatic osteosarcoma. , 2020, Cancer.

[21]  Y. Andéol,et al.  A c-ras-Ki oncogene is activated, amplified and overexpressed in a human osteosarcoma cell line. , 1987, Biochemical and biophysical research communications.

[22]  R. Nusse,et al.  Mechanisms of Wnt signaling in development. , 1998, Annual review of cell and developmental biology.

[23]  Stefan Mundlos,et al.  Modulation of GDF5/BRI‐b signalling through interaction with the tyrosine kinase receptor Ror2 , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[24]  Yusuke Nakamura,et al.  Frequent β‐Catenin Abnormalities in Bone and Soft‐tissue Tumors , 1999, Japanese journal of cancer research : Gann.

[25]  Stephen M Hewitt,et al.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.

[26]  S. Ferrari,et al.  Evaluation of P‐glycoprotein, HER‐2/ErbB‐2, p53, and Bcl‐2 in primary tumor and metachronous lung metastases in patients with high‐grade osteosarcoma , 2004, Cancer.

[27]  W Russe,et al.  [Osteogenic sarcoma]. , 1983, ZFA. Zeitschrift fur Allgemeinmedizin.

[28]  W. Forrester.  The Ror receptor tyrosine kinase family , 2002, Cellular and Molecular Life Sciences CMLS.

[29]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[30]  S. Ferrari,et al.  Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma , 2007, Current opinion in oncology.

[31]  G. Tortora,et al.  Key cancer cell signal transduction pathways as therapeutic targets. , 2006, European journal of cancer.

[32]  Baojin Fu,et al.  Accumulated Chromosomal Instability in Murine Bone Marrow Mesenchymal Stem Cells Leads to Malignant Transformation , 2006, Stem cells.

[33]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[34]  Yusuke Nakamura,et al.  Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. , 2002, DNA research : an international journal for rapid publication of reports on genes and genomes.

[35]  M. Patton,et al.  Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2 , 2000, Nature Genetics.

[36]  Yusuke Nakamura,et al.  Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. , 2004, International journal of oncology.

[37]  Edward W Scott,et al.  Stem-like cells in bone sarcomas: implications for tumorigenesis. , 2005, Neoplasia.

[38]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[39]  H. Tideman.  ERbB-2 expression is correlated with poor prognosis for patients with osteosarcoma , 1998 .

[40]  S. Burdach,et al.  A complex pattern of chemokine receptor expression is seen in osteosarcoma , 2008, BMC Cancer.

[41]  B. Komm,et al.  The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. , 2007, Molecular endocrinology.

[42]  Yusuke Nakamura,et al.  Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas , 2005, Oncogene.

[43]  Y. Furukawa,et al.  CDC20, a potential cancer therapeutic target, is negatively regulated by p53 , 2008, Oncogene.

[44]  Yusuke Nakamura,et al.  Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. , 2002, Cancer research.

[45]  P. Choong,et al.  A review of clinical and molecular prognostic factors in osteosarcoma , 2008, Journal of Cancer Research and Clinical Oncology.

[46]  P. Bodine,et al.  The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. , 2005, Molecular endocrinology.

[47]  G. Yancopoulos,et al.  Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development , 2000, Nature Genetics.

[48]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[49]  R. Nusse.  The Wnt gene family in tumorigenesis and in normal development , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  H. Horiuchi,et al.  ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma , 1996, Cancer.

[51]  F. Bertoni,et al.  Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. , 2006, Pathology, research and practice.